Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
BLA for Rockets LAD-I Gene Therapy Under Review by FDA Again October 14, 2025 The FDA has accepted Rocket Pharmaceuticals resubmission of a BLA for marnetegragene autotemcel (RP-L201, to be marketed as Kresladi), a genetically modified autologous hematopoietic stem cell therapy intended to treat LAD-I
GLP-1 RAs were significantly associated with gastrointestinal AEs, and the association was further attributed to liraglutide, dulaglutide, and semaglutide
Preliminary research suggests it may influence incretin hormone pathways, though clinical evidence supporting meaningful GLP-1 or GIP enhancement in humans is lacking
pAKK shows remarkable potential in combating Salmonella infections by upregulating intestinal barrier genes and secreting antimicrobial peptides (187)
The NIH factsheet explains that no tolerable upper intake level has been set for B12, because it has a low potential for toxicity in healthy people
By infusing glutathione IV therapy intravenously, the body can absorb higher concentrations of this antioxidant, resulting in brighter, more luminous skin
US$ 27.65
US$ 24.61
US$ 23.89
